所有图片(1)
别名:
羟基尿素
线性分子式:
NH2CONHOH
CAS号:
分子量:
76.05
Beilstein:
1741548
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
hydroxycarbamide
制造商/商品名称
EDQM
应用
pharmaceutical (small molecule)
格式
neat
储存温度
2-8°C
SMILES字符串
NC(=O)NO
InChI
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
InChI key
VSNHCAURESNICA-UHFFFAOYSA-N
基因信息
human ... RRM1(6240) , RRM2(6241) , RRM2B(50484)
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Hydroxycarbamide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
生化/生理作用
抗肿瘤剂。通过形成自由基硝基氧灭活核糖核苷还原酶，自由基硝基氧可结合到酶活性位点的酪氨酰自由基。这可阻断脱氧核苷酸的合成，从而抑制 DNA 合成，并且诱导细胞周期同步化或 S-期细胞死亡。
包装
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
预防措施声明
危险分类
Muta. 1B - Repr. 2
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Nancy S Green et al.
Pediatric blood & cancer, 56(2), 177-181 (2010-09-11)
Fetal hemoglobin (HbF) levels are generally inversely proportional to severity of sickle cell disease (SCD) for given sickle phenotypes. Molecular regulation of HbF occurs through complex interactions cis and trans to the beta globin gene locus. Novel insights made through
Russell E Ware
Blood, 115(26), 5300-5311 (2010-03-13)
Hydroxyurea has many characteristics of an ideal drug for sickle cell anemia (SCA) and provides therapeutic benefit through multiple mechanisms of action. Over the past 25 years, substantial experience has accumulated regarding its safety and efficacy for patients with SCA.
Nina Saban et al.
Cancer chemotherapy and pharmacology, 64(2), 213-221 (2009-04-08)
Hydroxyurea has been used for decades and it is still valuable for the treatment of some types of cancer. It inhibits ribonucleotide reductase (RNR) enzyme known to be crucial in the conversion of ribonucleotides into deoxyribonucleotides. However, nowadays the main
John J Strouse et al.
Pediatrics, 122(6), 1332-1342 (2008-12-03)
Hydroxyurea is the only approved medication for the treatment of sickle cell disease in adults; there are no approved drugs for children. Our goal was to synthesize the published literature on the efficacy, effectiveness, and toxicity of hydroxyurea in children
Pilvi Riihilä et al.
The Journal of investigative dermatology, 135(2), 579-588 (2014-09-04)
The incidence of cutaneous squamous cell carcinoma (cSCC) is rising worldwide. We have examined the role of complement components in the progression of cSCC. Analysis of cSCC cell lines (n=8) and normal human epidermal keratinocytes (n=11) with whole transcriptome profiling
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门